David Kerr
A5038254746- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Advances in Oncology and Radiotherapy
- Genetic Associations and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Ethics in Clinical Research
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Inflammatory mediators and NSAID effects
- Estrogen and related hormone effects
- Global Education and Multiculturalism
University of Oxford
2016-2025
Sutter Health
2025
John Radcliffe Hospital
2015-2024
Seattle University
2023
Churchill Hospital
2013-2023
Sichuan University
2021-2023
West China Hospital of Sichuan University
2021-2023
Chengdu University of Traditional Chinese Medicine
2023
Cancer Research UK Oxford Centre
2010-2022
Hoag Memorial Hospital Presbyterian
2022
The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results European Study Group for Pancreatic Cancer 1 Trial and update interim results.In a multicenter trial using two-by-two factorial design, we randomly assigned 73 patients with resected ductal adenocarcinoma to chemoradiotherapy alone (20 Gy over two-week period plus fluorouracil), 75 chemotherapy (fluorouracil), 72 both chemotherapy, 69 observation.The analysis was based 237 deaths among...
Purpose A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. shorter-term providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice. Methods Individual patient data were pooled from 18 randomized phase III cancer trials. Trials included 43 arms, a sample size 20,898 patients. The primary hypothesis was that disease-free (DFS), 3 follow-up, an...
Purpose It is uncertain whether modest benefits from adjuvant chemotherapy in stage II colorectal cancer justify the toxicity, cost, and inconvenience. We investigated usefulness of defective mismatch repair (dMMR), BRAF, KRAS mutations predicting tumor recurrence sensitivity to chemotherapy. Patients Methods Immunohistochemistry for dMMR pyrosequencing KRAS/BRAF were performed 1,913 patients randomly assigned between fluorouracil folinic acid no Quick Simple Reliable (QUASAR) trial. Results...
To assess the influence of resection margins on survival for patients with resected pancreatic cancer treated within context adjuvant European Study Group Pancreatic Cancer-1 (ESPAC-1) study.Pancreatic is associated a poor long-term rate only 10% to 15% after resection. Patients positive microscopic (R1) have worse survival, but it not known how they fare in studies.ESPAC-1, largest randomized study resectable ever performed, set out look at roles chemoradiation and chemotherapy....
Purpose This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC). Patients and Methods Fresh frozen tumor tissue from 188 stage I IV CRC undergoing surgery was analyzed using Agilent 44K oligonucleotide arrays. Median follow-up time 65.1 months, the majority of (83.6%) did not receive adjuvant chemotherapy. A nearest mean developed cross-validation procedure score all genes for their association...
We developed quantitative gene expression assays to assess recurrence risk and benefits from chemotherapy in patients with stage II colon cancer.We sought validation by using RNA extracted fixed paraffin-embedded primary tumor blocks 1,436 cancer the QUASAR (Quick Simple Reliable) study of adjuvant fluoropyrimidine versus surgery alone. A score (RS) a treatment (TS) were calculated levels 13 cancer-related genes (n = 7 n 6 benefit genes) five reference prespecified algorithms. Cox...
Abstract Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has strong heritable basis. We report genome-wide association analysis 34,627 CRC cases 71,379 controls European ancestry that identifies SNPs at 31 new risk loci. also identify eight independent the previously reported loci, further nine loci only identified in Asian populations. use situ promoter capture Hi-C (CHi-C), gene expression, silico annotation methods to likely target genes SNPs. Whilst...
Abstract HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers. One suggested anti‐ EGFR resistance mechanism colorectal cancer ( CRC ) aberrant MEK–AKT pathway activation through up‐regulation. We assessed ‐amplification/overexpression stage II–III and IV patients, assessing relationships KRAS / BRAF outcome. Pathological material was obtained from 1914 patients the QUASAR trial 1342 trials FOCUS PICCOLO ). Tissue microarrays were created for...